[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
Authors:
- 1 August 2018
- journal article
- letter
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (8) , e372-E372
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate CancerJournal of Nuclear Medicine, 2013
- High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancerThe Prostate, 2010